January 18, 2024
2 min watch
Save
VIDEO: Treatment intensification for patients with AML
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN DIEGO — In this video, Akriti Jain, MD, provides two updates on intensive treatment regimens for acute myeloid leukemia presented at ASH Annual Meeting and Exposition.
The first presentation assessed measurable residual disease-directed treatment intensification, according to Jain, a leukemia and myeloid disorders physician at Cleveland Clinic.
The second presentation investigated a regimen of venetoclax (Venclexta; Genentech, AbbVie), cytarabine and mitoxantrone for patients with relapsed/refractory AML.
“That’s also a promising addition of venetoclax to an intensive treatment regimen,” Jain said.
References:
- Ruhnke L, et al. Abstract 160. Presented at: ASH Annual Meeting and Exhibition; Dec. 9-12, 2023; San Diego.
- Russell N, et al. Abstract 830. Presented at: ASH Annual Meeting and Exhibition; Dec. 9-12, 2023; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Jain reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.